AbbVie is expecting to get its highly-anticipated all-oral hepatitis C drug approved soon and has geared up its manufacturing capacity to be ready. An expansion in Ireland adds to a string of projects the drugmaker has announced as the spinoff from Abbott Laboratories adds to its global manufacturing network.
As Europe prepares to open its clinical trial data vaults in a move toward greater transparency, the British Medical Journal is criticizing the European Medicines Agency for seemingly backtracking on its promises to make important information available to consumers.
In this week's EuroBiotech Report, Bayer became the most recent biopharma to tap Dutch biotech arGEN-X for its llama-based antibody discovery platform; Eli Lilly made its first-ever investment in a British venture fund; and British biotech Oxford BioMedica hopes to raise £25.7 million to finance its gene therapy pipeline. And more.
Eli Lilly has taken the unusual step of investing in Epidarex Capital's new, $80 million life sciences fund, with an eye to backing the Scotland-based group's portfolio of academic spinouts. This was Lilly's first investment in a U.K. venture fund.
Teva's $4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the needle on its planned replacement, enduring another rejection from European reviewers.
After an FDA rejection and an earlier negative opinion, Novartis' cardio treatment serelaxin has again failed to sway European regulators, and the drugmaker has resigned that its breakthrough-designated therapy will not hit any market this year.
Reversing an earlier rejection, European regulators are recommending early approval for PTC Therapeutics' ataluren, a treatment for Duchenne muscular dystrophy, news that more than doubled the biotech's share value in premarket trading.
After a manufacturing issue spiked its pitch for FDA approval, a new diabetes drug from Eli Lilly and Boehringer Ingelheim has secured European clearance, lining up to compete in a crowded market.
In the latest EuroBiotech Report, while critics of Pfizer's attempt to buy AstraZeneca spent the week celebrating a major blow to the deal, an awkward question remains: Exactly what has been "saved" from Pfizer's clutches? And more.
St. Jude Medical bucked the trend of bad renal denervation news, touting the newly released data from its studies of the CE-marked EnligHTN renal denervation system at the EuroPCR cardiovascular interventions conference in Paris.